Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphoribosylformylglycinamidine synthase (PFAS) is an enzyme that catalyzes a key ATP-dependent step in the de novo biosynthesis of purine nucleotides. It converts N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide (FGAR), L-glutamine, and water into 2-(formamido)-N1-(5-phospho-D-ribosyl)acetamidine (FGAM), L-glutamate, ADP, and phosphate. PFAS is essential for purine metabolism, which underpins DNA replication, transcription, energy metabolism, and other cellular processes requiring nucleotides. PFAS activity can be regulated by phosphorylation events mediated by ERK signaling pathways and via PW1 expression during cardiac injury.
Inhibition of de novo purine synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphoribosylformylglycinamidine synthase (PFAS).